AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01491386 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous Bone/LT-CAGE® Device
Description: LT-CAGE® device with autogenous bone taken from the iliac crest.
Study NCT01972308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Advocate
Description: Subject works with a Patient Advocate who coaches, models, and assists with preparations for a visit with the asthma doctor; attends the visit with permission of participant and provider; and confirms understanding. The PA facilitates scheduling, obtaining insurance coverage, overcoming patients' unique social and administrative barriers to accomplishing medical advice, and transfer of information between provider and patient.
Study NCT01972308 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Subjects receive asthma care from their proivders in the participating practices which generally follow asthma guidelines
Study NCT03585504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel contraceptive implant
Description: Etonogestrel contraceptive implant
Study NCT03691844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMZ001
Description: diclofenac gel
Study NCT03691844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00949117 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PediaSure
Description: Given orally
Study NCT00949117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyproheptadine hydrochloride
Description: Given orally
Study NCT01419808 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vascularized Bone Graft
Description: Vascularized bone graft in the treatment of Scaphoid Non-Union
Study NCT01419808 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Vascularized Bone Graft
Description: Non-Vascularized Bone Graft in the treatment of Scaphoid Non-unions
Study NCT03585504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel contraceptive implant
Description: Etonogestrel contraceptive implant
Study NCT00360269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: 25 to 100 mg daily
Study NCT00360269 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy
Description: Three sessions
Study NCT00360269 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Motivational enhancement therapy
Description: Three sessions
Study NCT00360269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25 to 100 mg daily
Study NCT01818180 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: URELL
Study NCT01818180 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02824926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapaconazole
Study NCT02824926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole
Study NCT03792061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategy Training
Description: This approach is different from traditional direct skill training, which emphasizes clinicians' responsibility on identifying their patients' challenges in performing activities and teaching patients task-specific problem-solving strategies. Strategy training, on the other hand, requires clinicians to take a role as a facilitator, guiding participants to learn through prompts and questions. In the training process, participants learn to develop their own problem-solving strategies and work through the problems they have, through which they can develop self-efficacy and confidence to manage participation challenges. Participants can also generalize the strategies they learn to other similar problems they encounter in daily life.
Study NCT02029443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Participants will receive acalabrutinib as stated in the arms' description.
Study NCT03691844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: diclofenac gel
Study NCT00883012 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent sub-unit influenza vaccine
Description: Composition per 0.5 ml dose:~Active substance:~Split Influenza virus\*, inactivated Strains for 2009 Southern hemisphere A/Brisbane/59/2007- like (H1N1) 15 micrograms\*\*, A/Brisbane/10/2007 (H3N2) - like strain (A/Brisbane/10/2007 (IVR-147) 15 micrograms\*\*, B/Florida/4/2006 - like strain (B/Brisbane/3/2007)15 micrograms\*\* Two doses, one month apart
Study NCT04065399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: revumenib
Description: revumenib orally
Study NCT04065399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobicistat
Description: Phase 1 Arm C participants will receive 150 mg cobicistat daily.
Study NCT00883012 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline, 0.5ml
Description: Saline IMI, 0.5ml. Two doses one month apart
Study NCT00374569 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gymnastic Routine
Description: A combination of gymnastic movements are performed
Study NCT02275715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training Program
Description: An 11-session manualized behavioral parent training program for the treatment of feeding problems teaching parents to use a range of behavioral procedures to address a variety of common feeding problems.
Study NCT00415428 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient adherence to national educational guidelines.
Study NCT00707707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2281
Description: Dose finding study to establish the appropriate dose of AZD2281
Study NCT00707707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous infusion over 1 hour
Study NCT00105482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Drug: Naltrexone 12.5 mg oral capsule once per day for 1 day then 25 mg oral capsule once per day for 27 weeks
Study NCT00105482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine replacement
Description: Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + naltrexone 25 mg oral capsule once per day
Study NCT02789423 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Pulp Capping using Dycal and Biodentine
Description: The operative procedure performed as follows: i)Administration of L.A and rubber dam isolation. ii)High-speed carious enamel removal. iii)Dentine mechanical curettage. iv)Manual final dentine curettage using a spoon excavator. v)Hemorrhage control by cotton pellet moistened with 2.5% sodium hypochlorite placed over the exposure for 1-2min. vi)The exposure site would then be dried with sterile cotton pellet.The operator shall apply the pulp capping agent(dycal/Biodentine)according to the manufacturer's instructions.And then another cover of glass ionomer is applied.This would be followed by permanent restoration.
Study NCT00418652 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: No TMS intervention
Description: In the no TMS condition, no simulation was given and no coil placed near participants' heads.
Study NCT00418652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS over the PO3 EEG site
Description: 10Hz TMS over the dorsal stream (PO3 EEG site)
Study NCT00418652 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS over the vertex
Description: 10Hz TMS for over vertex.
Study NCT00715351 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician
Study NCT00715351 — intervention group
Intervention type: DRUG
Intervention: insulin NPH
Description: Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician
Study NCT04547907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel+ trastuzumab+ patuzumab
Description: Nab-paclitaxel 125mg/m2 (days 1, 8, 15) + Trastuzumab (initial loading dose of 8 mg/kg, subsequent maintenance dose of 6 mg/kg) + Pertuzumab (initial loading dose of 840mg, subsequent maintenance dose of 420mg), every 21 days constitute a cycle.
Study NCT04547907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel+ carboplatin+ trastuzumab + patuzumab
Description: Docetaxel 75 mg/m2(day 1) + Carboplatin (AUC=6) (day 1) + Trastuzumab (initial loading dose of 8 mg/kg, subsequent maintenance dose of 6 mg/kg) + Pertuzumab (initial loading dose of 840mg, subsequent maintenance dose of 420mg), every 21 days constitute a cycle.
Study NCT04372147 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MMA embolization
Description: Patients in the intervention group will undergo a CT angiography scan of the supra aortic trunks, followed by MMA embolization procedure within 7 days of the burr-hole surgery in addition to standard medical care
Study NCT02639169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: apply live music through the techniques of music therapy
Study NCT03957499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml of normal saline (total volume 30 ml).(
Study NCT03957499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone/bupivacaine
Description: Ultrasound guided fascia iliaca compartment block (FICB) will be performed with 28 ml bupivacaine 0.25% + 2 ml dexamethasone (8mg) (total volume 30 ml)d using
Study NCT03957499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate/bupivacaine
Description: Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml magnesium sulphate (200mg) (total volume 30 ml).
Study NCT02387905 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Management of Therapy Complications
Description: Undergo vertebral body cement augmentation
Study NCT00105482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Transdermal nicotine replacement
Description: Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + naltrexone 25 mg oral capsule once per day
Study NCT00105482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral counseling
Description: Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.
Study NCT00105482 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral counseling
Description: Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.
Study NCT00380757 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bystander CPR using 30:2 ratio vs 15:2 ratio
Description: Participants will use 2 CPR techniques with different chest compression to ventilation ratios
Study NCT03606733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Custom suorachoroidal needle
Description: Custom made Supra Choroidal Space needle
Study NCT01812824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention (Virtual Patient Advocate)
Description: Intervention (Virtual Patient Advocate) participants will have access to the Gabby system for 6 months. There is no required dose or frequency that they have to log on to the system, but the investigators will suggest that they log on once a week.
Study NCT02387905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02387905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02170051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBSST-CCT
Study NCT02170051 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal focused supportive contact
Study NCT00038857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Megadose of CD34 Selected Progenitor Cells
Description: Haploidentical peripheral blood progenitor cell (PBPC) transplants on Day 0.
Study NCT00038857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m\^2 on day -8
Study NCT00038857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 10 mg/kg on day -7
Study NCT00038857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 160 mg/m\^2 over 4 days on days -6, -5, -4, -3
Study NCT02387905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02387905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02387905 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Description: Undergo standard stereotactic spinal radiosurgery
Study NCT02387905 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo standard stereotactic spinal radiosurgery
Study NCT01535599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-60371, 0.3% Otic Suspension
Study NCT01535599 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: AL-60371 Vehicle
Description: Inactive ingredients used as a placebo comparator
Study NCT01467050 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Application of STOPP/START criteria
Description: The researcher will apply the STOPP/START criteria to the cases randomised to this intervention. This will occur at the point of recruitment into the study and consists of applying STOPP/START criteria to the list of prescribed medications the patient is taking at that time point.~Where potentially inappropriate medications (PIM's) are identified using the intervention, these are highlighted to the medical team with primary responsibility for the patient both verbally and in writing. The relevant registrar will be contacted in person or via telephone by the researcher and informed of the PIM's in addition to a standard medication advice form inserted into the patients' notes also highlighting the PIM's.
Study NCT01467050 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Normal pharmaceutical care
Description: The normal process of medication prescription and review by the attending medical team.
Study NCT03179254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin continue
Description: Oral hypoglycemic agent continue on the day of ambulatory surgery
Study NCT03179254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin discontinue
Description: Oral hypoglycemic agent discontinue on the day of ambulatory surgery
Study NCT01528891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 0.5 micrograms/Kilogram one time bolus 5 minutes prior to the end of surgery
Study NCT01528891 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03800446 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Point of care ferritin test
Description: Point of care test that uses capillary blood sample from finger to determine ferritin level
Study NCT01940250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulphate
Description: MgSO4 IV infusion
Study NCT01940250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: H2O IV infusion
Study NCT02135029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bococizumab (PF-04950615;RN316)
Description: 150 mg every 2 weeks by subcutaneous injection for 24 weeks
Study NCT02135029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin PO QD
Study NCT02135029 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Bococizumab (PF-04950615;RN316)
Description: 150 mg every 2 weeks by subcutaneous injection for 24 weeks
Study NCT00038857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit ATG
Description: 1.5 mg/kg of Rabbit ATG a day times 4 over 4 days on days -6, -5, -4, -3.
Study NCT02135029 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for atorvastatin
Description: PO QD
Study NCT03262818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound
Description: -Will be performed by US technologists at Washington University School of Medicine and read by Dr. Cary Siegel or Dr. Kathryn Robinson
Study NCT03262818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound/Photoacoustic imaging
Description: -The light illumination for the photoacoustic imaging system is provided by a wavelength-tunable Ti:Sapphire laser (LOTIS TII), optically pumped by an Nd:YAG laser (LOTIS TII) at 532 nm wavelength.
Study NCT03030508 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT01818908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-EPOCH
Description: DA-EPOCH regimen
Study NCT02375568 — intervention group
Intervention type: OTHER
Intervention: 103024-F
Description: mesenchymal stem cell isolation
Study NCT03941457 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BiCAR-NK cells (ROBO1 CAR-NK cells)
Description: The subject will be observed for any side effects during this time and all the adverse events will be recorded.
Study NCT05215860 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco and areca nut cessation counselling with standard management for Oral Potentially Malignant Disorders
Description: WHO toolkit for Tobacco cessation (5A's and 5R's model)
Study NCT05215860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco and areca nut cessation counselling with standard management for Oral Potentially Malignant Disorders
Description: WHO toolkit for Tobacco cessation (5A's and 5R's model)
Study NCT05215860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visual exposure to personal intraoral photographs of oral lesions at baseline and review
Description: Chairside digital intraoral photographs of oral potentially malignant disorder with smart phone and showing the photograph to the participant explaining the abnormal areas of concern
Study NCT00211835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Individual psychotherapy focused on identifying and correcting maladaptive cognitions and behaviors with the goal of improving mood. The intervention has adapted CBT specifically to address cognitive deficits associated with TBI, which compound the cognitive distortions typical of depression. CBT therapists embed compensatory strategies within treatment sessions to address cognitive limitations of each participant.
Study NCT00211835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy
Description: A client-centered individual psychotherapy treatment approach designed to address depressive disorders commonly experienced by individuals following a TBI. In line with traditional supportive psychotherapy approaches, the objective of SPT is to improve the individual's ability to deal with problems of daily living more effectively through problem identification, praise, reassurance, encouragement, psychoeducation, advice, anticipatory guidance, and expanding awareness.
Study NCT01727115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Formula Feeding
Description: Assigned formula (Althera® or Nutramigen®) for a 4 weeks period.~* If the challenge is positive: The children continue the assigned formula~* If the challenge is negative: A Follow up formula is given~  * (Nan pro2) if child > 6 months~ * (Nan pro1) if child \< 6 months
Study NCT01727115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant Formula Feeding
Description: Assigned formula (Althera® or Nutramigen®) for a 4 weeks period.~* If the challenge is positive: The children continue the assigned formula~* If the challenge is negative: A Follow up formula is given~  * (Nan pro2) if child > 6 months~ * (Nan pro1) if child \< 6 months
Study NCT02114125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: group-based physical activity
Study NCT02114125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: individual-based, multi-domains cognitive training
Study NCT04401618 — intervention group
Intervention type: OTHER
Intervention: Retrospective evaluation of RMGI and GIC Class V Restorations
Description: Retrospective evaluation of RMGI and GIC Class V Restorations that were placed by dental students over the last three years were evaluated using the modified USPHS criteria using mirrors and probes.
Study NCT01083394 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTA
Description: PTA using a conventional balloon
Study NCT01083394 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTA with PEB
Description: PTA using a paclitaxel eluting balloon